Neurocognitive DisordersVISCOGNCT07205003
Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders
An observational study of Neurocognitive Disorders and Alzheimer's Disease, run by University Hospital, Rouen at 1 site in France.
Trial summary
The mechanical behavior of conductance arteries is viscoelastic. While the elastic component has been extensively studied, the viscous component has often been neglected for methodological reasons and also because it was considered weak. Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Neurocognitive Disorders, Alzheimer's Disease
- What is being tested?
- Assessment of carotid wall viscosity in patients with vascular dementia, Assessment of carotid wall viscosity in patients with Alzheimer's disease and Assessment of carotid wall viscosity in patients not presenting dementia.
- How many people
- 140 participants
- Where
- 1 siteFrance
- Study dates
- 15 Feb 2022to 15 May 2028
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: 140 sujets dont 55 sujets avec démence vasculaire et 55 avec une démence de type maladie d'Alzheimer et 30 avec plainte mnésique sans troubles neurocognitifs.
Who may be able to join
- Age over 70
- Memory consultation consultant (neurology or geriatrics)
- Brain MRI less than one year old or planned as part of the cognitive assessment performed.
- Patient diagnosed with Alzheimer's disease according to DSM-5 criteria or vascular dementia according to DSM-5 criteria, or presenting a memory complaint without evidence of a dementia-related condition.
- No objection from the patient or their caregiver.
- Patient covered by a health insurance plan
Who cannot join
- Known unilateral or bilateral carotid stenosis or history of carotid surgery
- Permanent CA/AF
- Patient presenting with confusion
- Known psychiatric illness (severe depression, psychosis, etc.)
- Non-vascular, non-Alzheimer's dementia (e.g., Lewy Body Dementia, Parkinsonian Dementia, Progressive Supranuclear Palsy)
- Refusal to participate
Show all 10Show fewer
- MMS less than or equal to 10
- Contraindication to performing an MRI
- Any acute decompensated pathology
- Patient under guardianship or curatorship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
University Rouen Hospital
Rouen, 76031
Frédéric FR ROCA, Doctor, 02 32 88 05 39 ext. +33, Frederic.Roca@chu-rouen.fr
About this study
Official title: Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders of Vascular Origin or Linked to Alzheimer's Disease
The mechanical behavior of conductance arteries is viscoelastic. While the elastic component has been extensively studied, the viscous component has often been neglected for methodological reasons and also because it was considered weak.
Unlike a purely elastic solid, which exhibits instantaneous deformation/relaxation upon application/discontinuation of a force, a viscoelastic solid is characterized, from a mechanical point of view, by a delay between the application or discontinuation of the force and deformation. Thus, at the arterial level, the elasticity of the arterial wall allows the internal diameter to increase proportionally to the blood pressure during systole. The viscous component will induce a delay in diameter restoration, resulting in a larger diameter at each pressure level during the diastolic phase compared to the systolic phase. This results in a shift between the systolic and diastolic curves of the pressure-diameter relationship, creating a hysteresis loop. From a thermodynamic point of view, while a purely elastic material fully restores the energy stored during the loading phase, viscoelastic arteries will incompletely restore this energy. Thus, the surface of the hysteresis loop reflects the energy dissipated during each cardiac cycle (WV), and the area under the loading phase curve represents the energy stored by the arterial wall (WE) during the latter. Thus, arterial wall viscosity (APV) can be expressed either as the absolute value of WV or as a function of the stored energy (WV/WE). Physiologically, this energy loss is low. Its increase could be accompanied by excessive energy dissipation, leading to increased cardiac work and cardio-circulatory decoupling. Conversely, low parietal viscosity could lead to damage to peripheral organs by excessive transmission of pulsatile energy to the periphery due to lack of damping.
Read the detailed description
Preliminary work in the laboratories has highlighted the role of vaso-relaxing endothelial factors and smooth muscle tone in the regulation of the Arterial Pulse Rate (APR) of the radial artery in the basal and stimulated state and the alteration of this stimulated regulation during Arterial Hypertension (AH). Furthermore, a decrease in relative carotid APR in middle-aged subjects compared to young subjects, and an increase in carotid APR in diabetic patients has been found in unpublished results. The link between aortic arterial stiffness and the existence of vascular dementia but also Alzheimer's is strongly suggested. Indeed, the increase in arterial stiffness could be responsible for an increase in pulsatility transmitted to the brain, participating in the accumulation of beta amyloid proteins. A probable inflammatory and oxidative stress component could also have an added deleterious role through the production of free radicals. Thus, previous studies have shown the existence of a link between arterial stiffness and the presence of leukoaraiosis, lacunae, microbleeds but also with brain volume and the progression of cerebral atrophy. These repercussions on the cerebral parenchyma are visible on MRI.
A link has also been suggested between increased arterial stiffness and impaired cognitive function (as demonstrated by neurocognitive tests) or the presence of markers of small vessel damage in neuroimaging (microbleeds, lacunae, leukoaraiosis). One hypothesis to explain this link is that arterial stiffness promotes impaired hippocampal microcirculation. Other studies have shown that carotid-femoral pressure wave velocity (CFV), a marker of large arterial stiffness, was higher in populations with Alzheimer's disease and vascular dementia than in older populations without cognitive impairment or with minor neurocognitive impairment.
However, no studies have evaluated the link between baseline VPA and vascular dementia or Alzheimer's disease.
Our study suggests that carotid VPA is associated with increased cerebrovascular injury, impaired cognitive testing, and the diagnosis of vascular dementia.
- Conditions
- Neurocognitive Disorders, Alzheimer's Disease
- Being tested
- Assessment of carotid wall viscosity in patients with vascular dementia, Assessment of carotid wall viscosity in patients with Alzheimer's disease, Assessment of carotid wall viscosity in patients not presenting dementia.
- Keywords
- carotid arterial wall viscosity
- Medical subject headings
- Neurocognitive Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Assessment of carotid wall viscosity in patients with vascular dementiaDiagnostic test
Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
Assessment of carotid wall viscosity in patients with Alzheimer's diseaseDiagnostic test
Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
Assessment of carotid wall viscosity in patients not presenting dementia.Diagnostic test
Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of the difference in relative arterial wall viscosity value of the common carotid artery of patients with vascular dementia compared to that of patients with Alzheimer's disease
Carotid wall viscosity will be assessed using a method developed in the pharmacology department, involving simultaneous and continuous measurement by two operators of local pressure and diameter at the right and left carotid arteries, combining echotracking (Vevo 3100®) with applanation tonometry (Millar®). Three successive measurements will be performed. These measurements will establish the diameter-pressure relationship, and their analysis will allow calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. The primary outcome measure will be the difference in carotid arterial wall viscosity between the two groups of subjects; it will be studied by analysis of variance (ANOVA).
Measured: Day 1
Evaluation of the difference in relative arterial wall viscosity value of the common carotid artery of patients with vascular dementia compared to that of patients not presenting dementia
Carotid wall viscosity will be assessed using a method developed in the pharmacology department, involving simultaneous and continuous measurement by two operators of local pressure and diameter at the right and left carotid arteries, combining echotracking (Vevo 3100®) with applanation tonometry (Millar®). Three successive measurements will be performed. These measurements will establish the diameter-pressure relationship, and their analysis will allow calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. The primary outcome measure will be the difference in carotid arterial wall viscosity between the two groups of subjects; it will be studied by analysis of variance (ANOVA).
Measured: enrollment visit
Secondary outcomes (9)
Evaluation of the link between arterial parietal viscosity of the common carotid artery and the intensity of cerebral vascular
Establishment of the correlation between the relative arterial parietal viscosity value of the common carotid artery and the intensity of lesions in MRI (Fazekas Classification). The Fazekas classification is a system used in neurology and neuroradiology to assess and grade the severity of cerebral white matter lesions observed on MRI. (Low grades (0-1): Changes are often age-related and without major symptoms. High grades (2-3): Indicate more severe impairment, associated with a greater risk of cognitive impairment)
Measured: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (MMSE)
Measurement of the correlation between the relative arterial parietal viscosity value and cognitive performance score MMSE. This is a short, standardized test used to assess overall cognitive function (score 27-30 Normal cognitive function; score 21-26 Mild cognitive impairment; score 10-20 Moderate impairment; score <10 Severe impairment)
Measured: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (Gröber test)
Measurement of the correlation between the relative arterial parietal viscosity value and cognitive performance score Gröber test. This neuropsychological test assesses verbal episodic memory, that is, the ability to memorize and recall verbal information. This score quantifies an individual's cognitive performance on the Gröber Verbal Memory Test. The score reflects the individual's ability to learn, retain, and recall a list of words presented orally. This assesses the quality of short-term and long-term memory. (A high score indicates good verbal episodic memory. A low score may indicate memory impairment, such as in Alzheimer's disease, other forms of dementia, or following a traumatic brain injury.)
Measured: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (verbal fluency)
Measurement of the correlation between the relative arterial parietal viscosity value and cognitive performance score verbal fluency. Verbal fluency assesses cognitive ability, measuring how easily a person can produce words in response to a given instruction, often within a limited time. (High score = good word production ability, preserved cognitive functioning. Low score = lexical difficulties, executive dysfunction, or cognitive slowing.)
Measured: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (cognitive performance score (BREF))
Measurement of the correlation between the relative arterial parietal viscosity value and cognitive performance score (BREF). The Cognitive Performance Score (BREF) is a standardized measure used to assess a person's overall cognitive functioning. The score is given on a scale where a lower score indicates better cognitive performance, and a higher score reflects a more marked deficit.
Measured: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (score oral naming score (DO80))
Measurement of the correlation between the relative arterial parietal viscosity value and cognitive performance score oral naming score (DO80) carry out by assessing the ability to find and produce the exact name of an object (lexical denomination).
Measured: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (number of successful gestural praxis)
Measurement of the correlation between the relative arterial parietal viscosity value and the number of successful gestural praxis perform by measuring the ability to perform voluntary, coordinated and purposeful gestures, particularly learned or symbolic gestures (such as greeting, using a tool, making a sign)..
Measured: enrollment visit
link between arterial stiffness (carotid and aortic) and the intensity of cerebral vascular lesions in MRI
Measurement of the correlation between segmental arterial stiffness of the common carotid artery (modulus, distensibility) and the intensity of cerebral vascular lesions in MRI.
Measured: Enrollment visit
Link between arterial stiffness (carotid and aortic) and the intensity of cerebral vascular lesions in MRI as well as with the severity of cognitive impairment
Measurement of the correlation between segmental arterial stiffness of the common carotid artery (modulus, distensibility) and severity of cognitive impairment
Measured: enrollment visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2025
- Study start15 Feb 2022
- Primary completion15 Nov 2027 (estimated)
- Study completion15 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurocognitive DisordersStudies of the same condition, open and under way.
- More trials run by University Hospital, RouenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 140 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University Hospital, Rouen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07205003
- Sponsor's protocol ID
- 2021/021/OB
- Other IDs
- 2021-A00291-40
- Acronym
- VISCOG
- Status last verified
- Jan 2026
- First submitted
- 24 Sep 2025
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data provided will be the property of the sponsor and will be used solely for its own research activities.
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders of Vascular Origin or Linked to Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT07205003
- Acronym / sponsor ID
- VISCOG / 2021/021/OB
- Conditions
- Neurocognitive Disorders, Alzheimer's Disease
- Keywords
- carotid arterial wall viscosity
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- University Hospital, RouenUniversity, hospital or other
- Study start
- 15 Feb 2022 (actual)
- Primary completion
- 15 Nov 2027 (estimated)
- Study completion
- 15 May 2028 (estimated)
- First posted
- 3 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The mechanical behavior of conductance arteries is viscoelastic. While the elastic component has been extensively studied, the viscous component has often been neglected for methodological reasons and also because it was considered weak.
Unlike a purely elastic solid, which exhibits instantaneous deformation/relaxation upon application/discontinuation of a force, a viscoelastic solid is characterized, from a mechanical point of view, by a delay between the application or discontinuation of the force and deformation. Thus, at the arterial level, the elasticity of the arterial wall allows the internal diameter to increase proportionally to the blood pressure during systole. The viscous component will induce a delay in diameter restoration, resulting in a larger diameter at each pressure level during the diastolic phase compared to the systolic phase. This results in a shift between the systolic and diastolic curves of the pressure-diameter relationship, creating a hysteresis loop. From a thermodynamic point of view, while a purely elastic material fully restores the energy stored during the loading phase, viscoelastic arteries will incompletely restore this energy. Thus, the surface of the hysteresis loop reflects the energy dissipated during each cardiac cycle (WV), and the area under the loading phase curve represents the energy stored by the arterial wall (WE) during the latter. Thus, arterial wall viscosity (APV) can be expressed either as the absolute value of WV or as a function of the stored energy (WV/WE). Physiologically, this energy loss is low. Its increase could be accompanied by excessive energy dissipation, leading to increased cardiac work and cardio-circulatory decoupling. Conversely, low parietal viscosity could lead to damage to peripheral organs by excessive transmission of pulsatile energy to the periphery due to lack of damping.
Detailed description
Preliminary work in the laboratories has highlighted the role of vaso-relaxing endothelial factors and smooth muscle tone in the regulation of the Arterial Pulse Rate (APR) of the radial artery in the basal and stimulated state and the alteration of this stimulated regulation during Arterial Hypertension (AH). Furthermore, a decrease in relative carotid APR in middle-aged subjects compared to young subjects, and an increase in carotid APR in diabetic patients has been found in unpublished results. The link between aortic arterial stiffness and the existence of vascular dementia but also Alzheimer's is strongly suggested. Indeed, the increase in arterial stiffness could be responsible for an increase in pulsatility transmitted to the brain, participating in the accumulation of beta amyloid proteins. A probable inflammatory and oxidative stress component could also have an added deleterious role through the production of free radicals. Thus, previous studies have shown the existence of a link between arterial stiffness and the presence of leukoaraiosis, lacunae, microbleeds but also with brain volume and the progression of cerebral atrophy. These repercussions on the cerebral parenchyma are visible on MRI.
A link has also been suggested between increased arterial stiffness and impaired cognitive function (as demonstrated by neurocognitive tests) or the presence of markers of small vessel damage in neuroimaging (microbleeds, lacunae, leukoaraiosis). One hypothesis to explain this link is that arterial stiffness promotes impaired hippocampal microcirculation. Other studies have shown that carotid-femoral pressure wave velocity (CFV), a marker of large arterial stiffness, was higher in populations with Alzheimer's disease and vascular dementia than in older populations without cognitive impairment or with minor neurocognitive impairment.
However, no studies have evaluated the link between baseline VPA and vascular dementia or Alzheimer's disease.
Our study suggests that carotid VPA is associated with increased cerebrovascular injury, impaired cognitive testing, and the diagnosis of vascular dementia.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- 140 sujets dont 55 sujets avec démence vasculaire et 55 avec une démence de type maladie d'Alzheimer et 30 avec plainte mnésique sans troubles neurocognitifs.
Key inclusion criteria (6 listed)
- Age over 70
- Memory consultation consultant (neurology or geriatrics)
- Brain MRI less than one year old or planned as part of the cognitive assessment performed.
- Patient diagnosed with Alzheimer's disease according to DSM-5 criteria or vascular dementia according to DSM-5 criteria, or presenting a memory complaint without evidence of a dementia-related condition.
- No objection from the patient or their caregiver.
Key exclusion criteria (10 listed)
- Known unilateral or bilateral carotid stenosis or history of carotid surgery
- Permanent CA/AF
- Patient presenting with confusion
- Known psychiatric illness (severe depression, psychosis, etc.)
- Non-vascular, non-Alzheimer's dementia (e.g., Lewy Body Dementia, Parkinsonian Dementia, Progressive Supranuclear Palsy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Assessment of carotid wall viscosity in patients with vascular dementiaCarotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. | Diagnostic test | – |
| Assessment of carotid wall viscosity in patients with Alzheimer's diseaseCarotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. | Diagnostic test | – |
| Assessment of carotid wall viscosity in patients not presenting dementia.Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. | Diagnostic test | – |
Primary outcome
Evaluation of the difference in relative arterial wall viscosity value of the common carotid artery of patients with vascular dementia compared to that of patients with Alzheimer's disease
Time frame: Day 1
Carotid wall viscosity will be assessed using a method developed in the pharmacology department, involving simultaneous and continuous measurement by two operators of local pressure and diameter at the right and left carotid arteries, combining echotracking (Vevo 3100®) with applanation tonometry (Millar®). Three successive measurements will be performed. These measurements will establish the diameter-pressure relationship, and their analysis will allow calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. The primary outcome measure will be the difference in carotid arterial wall viscosity between the two groups of subjects; it will be studied by analysis of variance (ANOVA).
Evaluation of the difference in relative arterial wall viscosity value of the common carotid artery of patients with vascular dementia compared to that of patients not presenting dementia
Time frame: enrollment visit
Carotid wall viscosity will be assessed using a method developed in the pharmacology department, involving simultaneous and continuous measurement by two operators of local pressure and diameter at the right and left carotid arteries, combining echotracking (Vevo 3100®) with applanation tonometry (Millar®). Three successive measurements will be performed. These measurements will establish the diameter-pressure relationship, and their analysis will allow calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle. The primary outcome measure will be the difference in carotid arterial wall viscosity between the two groups of subjects; it will be studied by analysis of variance (ANOVA).
9 secondary outcomes
Evaluation of the link between arterial parietal viscosity of the common carotid artery and the intensity of cerebral vascular
Time frame: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (MMSE)
Time frame: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (Gröber test)
Time frame: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (verbal fluency)
Time frame: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (cognitive performance score (BREF))
Time frame: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (score oral naming score (DO80))
Time frame: enrollment visit
Study of the link between arterial parietal viscosity of the common carotid artery and the severity of cognitive impairment (number of successful gestural praxis)
Time frame: enrollment visit
link between arterial stiffness (carotid and aortic) and the intensity of cerebral vascular lesions in MRI
Time frame: Enrollment visit
Link between arterial stiffness (carotid and aortic) and the intensity of cerebral vascular lesions in MRI as well as with the severity of cognitive impairment
Time frame: enrollment visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No. The data provided will be the property of the sponsor and will be used solely for its own research activities.
Related trials for Neurocognitive Disorders
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurocognitive Disorders and Alzheimer's Disease, run by University Hospital, Rouen at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Frédéric FR ROCA, Doctor (02 32 88 05 39 ext. +33, Frederic.Roca@chu-rouen.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of the difference in relative arterial wall viscosity value of the common carotid artery of patients with vascular dementia compared to that of patients with Alzheimer's disease (time frame: Day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.